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Abstract
Introduction Approximately one third of all patients with
cardiogenic shock suffer from acute kidney injury. Percutaneous
coronary intervention, intra-aortic balloon pump, and continuous
renal replacement therapy (CRRT) require effective antiplatelet
therapy and anticoagulation, resulting in a high risk for platelet
loss and bleeding events. The reversible platelet glycoprotein
IIb/IIIa receptor inhibitor tirofiban was investigated to preserve
platelet number and activation in a prospective open-blinded
endpoint evaluation study.
Methods Forty patients with cardiogenic shock and acute
kidney injury requiring CRRT were randomly assigned to two
groups receiving unfractioned heparin (UFH) (n = 20) or a
combined anticoagulation with UFH and tirofiban (n = 20). The
primary endpoint was platelet loss during CRRT. Secondary
endpoints were urea reduction, haemofilter life span, bleeding
events, and necessity for platelet transfusions.
Results In UFH-treated patients, the percentage of platelet-
monocyte aggregates significantly increased (P < 0.001) and
consecutively platelet cell count significantly decreased (P <
0.001). In contrast, combined treatment with UFH and tirofiban
significantly decreased platelet-monocyte aggregates and
platelet numbers (P < 0.001).
Conclusions This pilot study provides evidence that the use of
tirofiban in addition to UFH prevents platelet loss and preserves
platelet function in patients with cardiogenic shock and acute
kidney injury requiring CRRT. The pathophysiological inhibition
of platelet aggregation and platelet-monocyte interaction
appears to be causally involved.
Introduction
Approximately one third of all patients with cardiogenic shock
suffer from acute kidney injury. This increases in-hospital mor-
tality from 53% to 87% [1]. Early revascularisation, intra-aortic
balloon pump (IABP), and antithrombotic therapy improve out-
comes in cardiogenic shock [2]. In cases of acute kidney injury
with necessity for continuous renal replacement therapy
(CRRT), effective anticoagulation is required. However, exces-
sive anticoagulation in critically ill patients receiving CRRT may
cause changes in platelet function, platelet loss, and bleeding
events [3,4].
The contact of blood with surfaces of the extracorporeal mem-
brane circuits and different anticoagulants leads to platelet
and leukocyte activation [5,6] and platelet-leukocyte coaggre-
gation [7,8]. All of these interactions result in glycoprotein
(GP) IIb/IIIa receptor activation that becomes capable of bind-
ing soluble fibrinogen [9]. GP IIb/IIIa receptor antagonists pri-
marily act on the platelet surface by inhibition of fibrinogen
binding that is essential for platelet bridging and aggregate
formation [10].
Tirofiban is a reversible short-acting inhibitor of platelet GP IIb/
IIIa receptors used in acute coronary syndromes and cardiac
interventions [11]. The hypothesis that tirofiban preserves
platelet number and function and shortens postoperative
bleeding times was first described in baboons [12] and in
patients with heparin-induced thrombocytopenia type II (HIT-Page 1 of 9
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this study was to prove the efficacy of tirofiban on platelet pro-
tection and safety in critically ill patients with cardiogenic
shock and necessity for CRRT receiving either conventional
therapy with unfractionated heparin (UFH) or additional
tirofiban.
Materials and methods
The PROBE (prospective randomised open-blinded endpoint)
design study was approved by the ethics committee of the
state medical board. Patients with cardiogenic shock (n =
187) and acute kidney injuries with necessity for CRRT (n =
52) were evaluated from January 2006 to December 2007.
Cardiogenic shock was confirmed by both clinical and haemo-
dynamic criteria. The clinical criteria were hypotension (systo-
lic blood pressure of less than 90 mm Hg for at least 30
minutes or the need for supportive vasoactive medications to
maintain a systolic blood pressure of greater than 90 mm Hg)
and evidence of end-organ hypoperfusion (cool, diaphoretic
extremities). Haemodynamic criteria were a reduced cardiac
index (<2.2 L/minute per m2) and the presence of elevated
pulmonary capillary occlusion pressure (>15 mm Hg) [15].
Acute kidney injury with necessity for CRRT was defined as a
urine output of less than 0.5 mL/kg per hour for 6 hours and/
or an increase in serum creatinine of greater than or equal to
1.5 mg/dL within 24 hours according to the RIFLE (Risk, Injury,
Failure, Loss, and End-stage kidney disease) criteria grade risk
of renal dysfunction [16]. After admission to the intensive care
unit (ICU) and after informed consent was given, all study par-
ticipants (n = 40) were randomly assigned using a computer
algorithm: UFH (n = 20) versus UFH + tirofiban (n = 20). Fig-
ure 1 outlines data on patient enrolment, exclusion criteria, and
follow-up. The primary endpoint was platelet loss during
CRRT. Secondary outcomes were the efficacy of CRRT,
measured by steady-state blood urea nitrogen (BUN) during
CRRT, the need for platelet substitution (platelet count of less
than 20 × 109/L) and major bleeding signs. Major bleeding
included any bleeding requiring surgical intervention with a
timely connection with CRRT, bleeding documented by com-
puted tomography and/or ultrasound (intracerebral as well as
retroperitoneal, abdominal, intestinal, or urogenital) or a
decrease in haemoglobin of greater than 5 g/dL within 72
hours with a timely connection with CRRT. Minor bleeding
involves a haemoglobin drop of less than or equal to 5 g/dL
with or without an identified bleeding site.
CRRT was performed as continuous veno-venous haemodial-
ysis, using a pump system (ADM; Fresenius, Bad Homburg,
Germany) and capillary polysulfone haemofilters (Ultraflux® AV
1000S; Fresenius). Blood flow ranged from 100 to 120 mL/
hour. Dialysis flow was, on average, 2,000 mL/hour. The ultra-
filtration rate was adjusted to patient hydratation and haemo-
dynamic status. Haemofilters and tubing were changed
routinely every 24 hours according to the manufacturer's rec-
ommendations. Therefore, blood was reinfused to the patient
and the entire set of single-use tubes was changed together
with the haemofilter. Blood products were administered during
a CRRT pause if necessary when haemofilters were changed.
The efficacy of CRRT was measured by mean treatment dose
and steady-state BUN during CRRT [17]. The study drugs
standard unfractioned heparin (UFH) and tirofiban were
administered into the extracorporeal circuit as a prefilter infu-
sion. All patients received UFH (Heparin-Natrium-ratiopharm®;
ratiopharm GmbH, Ulm, Germany) by intravenous bolus appli-
cation of 80 IU/kg followed by a continuous infusion with 18
IU/kg per hour. For UFH dose titration, plasma activated partial
thromboplastin time (aPTT) was measured every hour until a
two- to three-fold aPTT was reached. In cases of a steady
state, CRRT was started and aPTT was measured twice daily.
The short-acting reversible GP IIb/IIIa inhibitor tirofiban (Aggr-
astat®; MSD Sharp & Dohme GmbH, Haar, Germany) has a
protein binding of 65% and an elimination half-life of 1.5 to 2
hours predominantly achieved via the renal pathway. Accord-
ing to the manufacturer's recommendations for severe renal
insufficiency (creatinine clearance of less than 30 mL/minute),
patients of the tirofiban group received, in addition to UFH,
tirofiban by intravenous bolus application of 0.2 μg/kg per
minute over 30 minutes followed by a continuous infusion with
0.05 μg/kg per minute. According to clinical guidelines, pro-
phylactic platelet transfusions are recommended beyond a
platelet count of less than 10 × 109/L [18]. Because of the off-
label use of tirofiban, the threshold level for prophylactic plate-
let transfusion was changed to 20 × 109/L.
Laboratory tests
To determine changes in haemostasis during the passage of
blood through the extracorporeal circuit, blood was sampled in
citrate tubes from the efferent line of the extracorporeal circu-
lation (postfilter). All tests were performed in duplicate. Blood
samples for analysis of full clinical chemistry, haematology,
and platelet-monocyte aggregates were taken before starting
CRRT and the following 4 days after starting treatment. The
bleeding time was measured by the standardised Ivy method
[19]. Other causes of platelet loss were excluded by HIT-II
screening tests using the particle gel immunoassay (ID-HPF-
4; DiaMed, Cressier, Switzerland) for rapid detection and the
enzyme-linked immunosorbent assay for discovering antibod-
ies (IgG, IgA, and IgM) to heparin-platelet factor-4 complexes.
Both HIT-II tests were done for all patients. Flow cytometry is
a sensitive technique that permits the use of whole blood to
assess platelet function in a physiological manner although the
interaction of blood with the endothelium is excluded [20].
Staining platelets with antibodies was performed immediately
after blood collection, avoiding artificial platelet activation and
aggregation. Platelets were identified by monoclonal anti-
human antibodies directed against CD41 (clone HIP8, phyco-
erythrin-conjugated; BD Pharmingen, Heidelberg, Germany),
the activated form of GP IIb/IIIa receptors by PAC-1 (clone
PAC-1, fluorescein isothiocyanate-conjugated; BD Pharmin-
gen), and monocytes by CD14 (clone RMO52, phycoerythrin-Page 2 of 9
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many). Increases in PAC-1 have been shown to be directly
correlated with the activation of GP IIb/IIIa binding to fibrino-
gen and/or monocytes. Measurements were performed by
flow cytometer (FACSCalibur; Becton Dickinson, Heidelberg,
Germany) and the Cellquest software system (Becton Dickin-
son, Heidelberg, Germany). Monocytes were selectively gated
for analysis by forward scatter, side scatter, and CD14-
PECy5. The percentages of PAC-1+/CD41a+/CD14+ platelet-
monocyte aggregates were measured. Nonspecific immun-
ofluorescence was determined using unspecific control mon-
oclonal antibodies.
Statistical methods
The sample size calculation was performed by the software of
the Survey System (Creative Research Systems, Petaluma,
Figure 1
Study flowchart. Patients were randomly assigned in different anticoagulation regimens (unfractioned heparin [UFH] versus UFH + tirofiban), sepa-
rated according to the concomitant therapy with or without intra-aortic balloon pump (IABP). Furthermore, the concomitant antiplatelet therapy and 
the number of patients included in each subgroup were added. Exclusion criteria include cardiopulmonary resuscitation, suspected concomitant 
sepsis defined by haemodynamic criteria (reduced systemic vascular resistance), a platelet count of less than 100 × 109/L, or major bleeding signs 
(one patient retroperitoneal and one patient gastric haemorrhage). aPTT, activated partial thromboplastin time.Page 3 of 9
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acceptations: a platelet loss of more than 50% to baseline and
a variability of platelet counts of 15%. To detect platelet loss
with a power of 95%, a sample size of at least 20 patients in
each study group was required. To compare the two treatment
regimens, the Mann-Whitney U test and analysis of variance
were used. Data were given as mean ± standard deviation. Dif-
ferences were considered significant if the P value was less
than 0.05. Observed-to-expected (O/E) mortality ratios were
reported for each group using the observed-to-SAPS II (Sim-
plified Acute Physiology Score) expected rates per group.
Ninety-five percent confidence intervals were calculated.
Results
Forty patients with cardiogenic shock and acute kidney injuries
receiving CRRT were studied for an alternative anticoagulation
regimen with the GP IIb/IIIa receptor antagonist tirofiban.
Baseline characteristics of the patients are shown in Table 1.
All baseline characteristics were well balanced between the
treatment groups. Thirty-six of the patients had an acute myo-
cardial infarction, and only four patients had a cardiogenic
shock based on acute on chronic heart failure. Clinical proce-
dures are summarised in Table 2. All patients with acute coro-
nary syndromes received a percutaneous coronary
intervention, and in 23 cases an IABP was implanted. Most
patients received vasoactive therapy at randomisation and
during the whole study period of 4 days.
Platelet counts are shown in Figure 2. Baseline platelet counts
in the two treatment groups were equivalent (194 ± 39.5 ver-
sus 216 ± 64.3 × 109/L, P = n.s. [not significant], n = 20).
Already after 1 day, patients assigned to tirofiban + UFH had
a significant higher platelet count compared with patients
assigned to UFH (172 ± 52.9 versus 121 ± 49.2 × 109/L, P
= 0.003, n = 20). This difference between the two treatment
groups continued over the study period up to 4 days (158 ±
45.3 versus 87.3 ± 41.1 × 109/L, P < 0.0001, n = 20).
The influence of IABP treatment on platelet count is shown in
Figure 2. At day 2, which is the mean IABP duration, there was
no significant difference in platelet count between the UFH
groups with or without IABP. In the same way, no significant
differences could be observed in the tirofiban groups with or
Table 1
Demographic and baseline clinical characteristics of patients
UFH (n = 20) UFH + tirofiban (n = 20) P value
Demographic data
Age in years, median (range) 71 (44, 85) 70 (52, 81) 0.932
Female/male, number 8/12 9/11 0.757
Severity of illness scores
APACHE II score, median (range) 27 (18, 34) 28 (18, 34) 0.523
SAPS II, median (range) 46 (31, 66) 48 (30, 64) 0.768
Cardiogenic shock: reasons and haemodynamics at admission
Acute coronary syndromes, number 17 19 0.304
Acute decompensation of CHF, number 3 1 0.304
Left ventricular ejection fraction as a percentage, median (range) 31 (20, 57) 30 (18, 54) 0.446
Cardiac index in L/minute per square metre, median (range) 2 (1.4, 2.4) 2 (1.6, 2.4) 0.955
Renal failure: reasons and parameters at admission
Acute kidney injury, number 16 17 0.688
Acute decompensation of CRI, number 4 3 0.688
Creatinine in mg/dL, mean ± SD 2.9 ± 0.3 2.5 ± 0.2 0.788
Blood urea nitrogen in mg/dL, mean ± SD 72 ± 23.3 70 ± 24.1 0.734
Haematology
Platelet count, × 109/L, mean ± SD 216 ± 64.3 194 ± 39.5 0.212
Monocyte count, × 106/L, mean ± SD 1,059 ± 85.4 981 ± 103 0.561
Platelet-monocyte aggregates as a percentage, mean ± SD 20.2 ± 5.9 20.8 ± 6.1 0.751
APACHE, Acute Physiology and Chronic Health Evaluation; CHF, chronic heart failure; CRI, chronic renal insufficiency; SAPS, Simplified Acute 
Physiology Score; SD, standard deviation; UFH, unfractioned heparin.Page 4 of 9
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patients with or without IABP were detected on days 3 and 4.
After discontinuation of IABP, no significant increase in plate-
let count was observed for either the UFH or the tirofiban
group until the end of the study period.
Besides the different anticoagulation with UFH or UFH and
tirofiban, the patients were treated with different antiplatelet
regimens (no antiplatelets, acetylsalicylic acid alone, or com-
bined antiplatelet therapy with acetylsalicylic acid and
thienopyridine) (Table 2). Since the number of patients in the
subgroups with no antiplatelet therapy or with acetylsalicylic
acid alone was too low, no statistical analysis could be per-
formed. But, as shown in Figure 3, the course of platelet count
was comparable in the three antiplatelet subgroups during the
whole study period.
The efficacy of CRRT was estimated by mean treatment dose,
steady-state BUN during CRRT, and haemofilter life span. The
calculated mean treatment dose was 25 to 30 mL/kg per hour
in both anticoagulation regimens and confirmed by an accept-
able steady-state BUN during CRRT (Table 2).
The platelet transfusion threshold was defined as a platelet
count of less than 20 × 109/L. During the study period, in three
patients of the UFH group, a platelet loss of less than 20 ×
109/L was registered without any bleeding signs. Two patients
received one platelet unit and one patient needed two units for
platelet increase. The number of platelet units related to the
cumulative days of CRRT was calculated as 0.05 ± 0.02. In
the tirofiban group, no platelet transfusion was necessary.
Thus, the difference of platelet transfusions between the two
groups was significant (P = 0.016, n = 20) (Table 3).
The study was not powered for mortality. The in-hospital mor-
tality rates were 35% in the UFH + tirofiban group and 40% in
the UFH group. ICU mortality, hospital mortality, O/E mortality
ratios, and 95% confidence intervals were calculated (Table
3).
In all patients, the baseline levels of monocytes were not differ-
ent between the two anticoagulation regimens (UFH +
tirofiban versus UFH: 981 ± 103.6 versus 1,059 ± 85.4 ×
106/L, n = 20, P = n.s.). During CRRT with UFH + tirofiban,
monocyte counts increased significantly (1,394 ± 151 versus
945 ± 77.3 × 106/L, n = 20, P = 0.012). The percentage of
PAC-1/CD41a-positive monocytes before starting CRRT was
equivalent between the two anticoagulation regimens (20.8%
± 6.1% versus 20.2% ± 5.9%, n = 20, P = n.s.). Within 24
hours, the combined UFH + tirofiban anticoagulation resulted
in a decrease of PAC-1/CD41a-positive platelet-monocyte
coaggregates whereas with UFH alone these coaggregates
increased (9.5% ± 5.8% versus 27.5% ± 9.3%, n = 20, P <
0.001). The follow-up of 4 days presented a further decrease
of platelet-monocyte coaggregates in the tirofiban group;
within the UFH group, the coaggregates remained stable but
elevated to baseline (27.5% ± 9.3% versus 20.2% ± 5.9%, n
= 20, P < 0.001). This difference between the two anticoagu-
lation regimens was already present after 24 hours of treat-
ment (Figure 4).
Discussion
In a pilot study, we investigated the possible use and effective-
ness of the reversible platelet GP IIb/IIIa receptor inhibitor
tirofiban to preserve platelet number and function during
CRRT in patients with cardiogenic shock. Tirofiban additional
to UFH for anticoagulation apparently prevented platelet loss
Figure 2
Mean platelet counts during the study period in patients treated with unfractioned heparin (UFH) versus UFH + tirofiban and with or without intra-aortic balloon pump (IABP)
aortic balloon pump (IABP). Data are shown as mean ± standard deviation. n.s., not significant.Page 5 of 9
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of the activated platelet fibrinogen receptor GP IIb/IIIa (PAC-
1) by tirofiban results in an inhibition of platelet-leukocyte inter-
action and aggregation [7,8,21]. We examined changes in
platelet loss and platelet-monocyte coaggregates by analysing
the platelet-specific CD41a and PAC-1 antigen on monocytes
using three-color flow cytometry as whole-blood technique.
The percentage of platelet-monocyte coaggregates showed a
highly significant decrease by combined anticoagulation with
UFH and tirofiban. Platelet-monocyte aggregates were shown
to promote monocyte adhesion to endothelium and to induce
proinflammation [22-25]. Our findings suggest that the com-
bined anticoagulation with UFH and tirofiban during CRRT
inhibits platelet activation and platelet-monocyte interactions
with consequences for platelet protection and antithrombotic
and anti-inflammatory effects. In contrast, the treatment with
UFH alone increased platelet-monocyte binding.
Platelet loss under CRRT in the UFH group was marked. This
may be related to the critically ill patients with cardiogenic
shock combined with acute kidney injury. Our results are com-
parable to other examinations of critically ill patients with mul-
tiple organ dysfunction syndrome and acute kidney injuries
[26]. Neither the concomitant treatment with intra-aortic coun-
terpulsation nor the antiplatelet therapy with acetylsalicylic
acid and thienopyridine had an effect on the platelet loss
between these subgroups.
The efficacy of CRRT assessed by mean treatment doses and
steady-state BUN during CRRT was comparable in the two
treatment groups. Despite the different anticoagulation regi-
mens and the higher potency of anticoagulation within the
tirofiban + UFH group, this therapy was not associated with an
increased number of bleeding events. To minimise the risk of
bleeding, tirofiban and UFH were administered into the extra-
corporeal circuit as a prefilter infusion. The study was not
focused on bleeding events and therefore an analysis regard-
ing bleeding events would be totally underpowered. But as a
result, no clinically important bleedings were detected and no
transfusions of red blood cells or platelet units were necessary
Table 2
Clinical procedures
UFH (n = 20) UFH + tirofiban (n = 20) P value
Cardiac procedures
Coronary angiography, number 18 19 0.560
Percutaneous coronary intervention, number 15 18 0.560
Intra-aortic balloon pump, number 11 12 0.876
Intra-aortic balloon pump duration in hours, mean ± SD 48 ± 14.4 50 ± 12.5 0.757
Haemodialysis characteristics
Treatment dose in mL/kg per hour, mean ± SD 28 ± 2.5 28 ± 2.9 0.381
Blood urea nitrogen (BUN)
Pretreatment BUN in mg/dL, mean ± SD 72 ± 23.3 70 ± 24.1 0.734
Steady-state BUN during CRRT in mg/dL, mean ± SD 32 ± 18.1 31 ± 22.1 0.734
Antiplatelet therapy and anticoagulation
No antiplatelets, number 3 1 -
Acetylsalicylic acid alone, number 2 1 -
Acetylsalicylic acid and thienopyridine, number 15 18 -
UFH, number (dose in IU/kg per hour, mean ± SD) 20 (18.4 ± 0.6) 20 (18.2 ± 0.8) 0.872
Activated partial thromboplastin time in seconds, mean ± SD 64 ± 13.2 62 ± 11.8 0.621
Ivy bleeding time in seconds, mean ± SD 422 ± 58.1 599 ± 118.1 0.003
Further concomitant therapy
Dobutamine, number (dose in μg/kg per minute, mean ± SD) 18 (6 ± 2.8) 19 (6 ± 3.2) 0.560
Norepinephrine, number (dose in μg/kg per minute, mean ± SD) 14 (0.2 ± 0.1) 13 (0.2 ± 0.15) 0.744
Opioids and benzodiazepins, number 12 14 0.519
Mechanical ventilation, number 12 14 0.519
CRRT, continuous renal replacement therapy; SD, standard deviation; UFH, unfractioned heparin.Page 6 of 9
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agulation. Nevertheless, further studies are warranted to
ascertain the safety of an anticoagulation regimen with
tirofiban + UFH during long-term CRRT.
One might argue that the study could be limited by (a) the
open-label character of its design, (b) the small number of
patients, (c) the lack of a specific antidote for tirofiban, and (d)
missing data on long-term efficacy and bleeding events of
tirofiban during CRRT. Because of the pilot-study character
and the off-label use of tirofiban during CRRT, the physicians
were not blinded. However, clinical evaluation and determina-
tion of primary endpoints were done separately by clinical and
experimental investigators, the latter of which were blinded to
the clinical data of the patients. As there is no specific antidote
for tirofiban in cases of bleeding events, donor platelets should
be transfused and haemofiltration is suggested for extracor-
poreal elimination of tirofiban [27]. A recent development of a
rapid whole-blood point-of-care platelet function assay, the
rapid platelet function assay, now allows for the bedside
monitoring of platelet inhibition by GP IIb/IIIa receptor antago-
nists [28]. Further investigations with larger numbers of
patients are necessary for the determination of haemofilter run
times, long-term efficacy, and bleeding events of tirofiban dur-
ing CRRT.
Conclusion
The GP IIb/IIIa receptor antagonist tirofiban inhibits platelet
activation and platelet-monocyte interaction. Its use in addition
to UFH during CRRT prevents platelet loss and preserves
platelet function.
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Table 3
Primary and secondary endpoints
UFH (n = 20) UFH + tirofiban (n = 20) P value
Platelet/Monocyte counts at the end of CRRT
Platelet count, × 109/L, mean ± SD 87 ± 41.1 158 ± 45.3 0.001
Monocyte count, × 106/L, mean ± SD 945 ± 77.3 1,394 ± 151 0.012
Platelet-monocyte aggregates as a percentage, mean ± SD 27.5 ± 9.3 3.9 ± 2.1 0.001
Bleeding events during CRRT
Minor bleeding, number 2 1 0.560
Major bleeding, number 0 0 1
Platelet transfusions during CRRT
Platelet units per patient per day, mean ± SD 0.05 ± 0.02 0 0.016
Outcome
Intensive care unit mortality rate, number (percentage) 8 (40) 7 (35) 0.752
Hospital mortality rate, number (percentage) 8 (40) 7 (35) 0.752
SAPS II predicted mortality rate as a percentage 36.9 41.4 -
Observed-to-expected mortality ratio 1.08 0.85 -
95% confidence interval for the observed-to-expected mortality ratio 0.46, 1.97 0.34, 1.59 -
Values are presented as number of patients or mean ± standard deviation (SD). CRRT, continuous renal replacement therapy; SAPS, Simplified 
Acute Physiology Score; UFH, unfractioned heparin.
Figure 4
Mean platelet-monocyte aggregates during the study period in patients treated with unfractioned heparin (UFH) versus UFH + tirofiban and with or without intra-aortic balloon pump (IABP)
without intra-aortic balloon pump (IABP). Data are shown as mean ± standard deviation. n.s., not significant.Page 8 of 9
(page number not for citation purposes)
Available online http://ccforum.com/content/12/4/R111Acknowledgements
We would like to thank all of the people who were involved in the study.
References
1. Koreny M, Karth GD, Geppert A, Neunteufl T, Priglinger U, Heinz
G, Siostrzonek P: Prognosis of patients who develop acute
renal failure during the first 24 hours of cardiogenic shock
after myocardial infarction.  Am J Med 2002, 112:115-119.
2. Hochmann JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon
V, Webb JG, Steingart R, Picard MH, Menegus MA, Boland J, San-
born T, Buller CE, Modur S, Forman R, Desvigne-Nickens P,
Jacobs AK, Slater JN, LeJemtel TH, SHOCK Investigators: Should
we emergently revascularize occluded coronaries for cardio-
genic shock: one-year survival following early revasculariza-
tion for cardiogenic shock.  JAMA 2001, 285:190-192.
3. Bold J, Menges T, Wollbrück M, Sonneborn S, Hempelmann G:
Continuous hemofiltration and platelet function in critically ill
patients.  Crit Care Med 1994, 22:1155-1160.
4. Mulder J, Tan HK, Bellomo R, Silvester W: Platelet loss across
hemofilter during continuous hemofiltration.  Int J Artif Organs
2003, 26:906-912.
5. Notohamiprodjo M, Andrassy K, Bommer J, Ritz E: Dialysis mem-
branes and coagulation system.  Blood 1986, 4:130-141.
6. Lins LE, Boberg U, Jacobson SH, Kjellstrand C, Ljungberg B,
Skroder R: The influence of dialyzer geometry on blood coag-
ulation and biocompatibility.  Clin Nephrol 1993, 40:281-285.
7. Spangenberg P, Redlich H, Bergmann I, Losche W, Gotzrath M,
Kehrel B: The platelet glycoprotein IIb-IIIa complex is involved
in the adhesion of activated platelets to leukocytes.  Thromb
Haemost 1993, 70:514-521.
8. Gawaz MP, Mujais SK, Schmidt B, Blumenstein M, Gurland HJ:
Platelet-leukocyte aggregates during hemodialysis: effect of
membrane type.  Artif Organs 1999, 23:29-36.
9. Kawabata K, Nakai S, Miwa M, Sugiura T, Otsuaka Y, Shinzato T,
Hiki Y, Tomimatsu I, Ushida Y, Hosono F, Maeda K: Platelet GP
IIb/IIIa is activated and platelet-leukocyte coaggregates
formed in vivo during hemodialysis.  Nephron 2002,
90:391-400.
10. Gawaz MP, Mujais SK, Schmidt B, Burland HJ: Platelet-leukocyte
aggregation during hemodialysis.  Kidney Int 1994,
46:489-495.
11. The PRISM-Plus Investigators: Inhibition of the platelet glyco-
protein IIb/IIIa receptor with tirofiban in unstable angina and
non-Q-wave myocardial infarction.  N Engl J Med 1998,
338:1488-1497.
12. Hiramatsu Y, Gikakis N, Anderson HL III, Gorman JH III, Marcinkie-
wicz C, Gould RJ, Niewiarowski S, Edmunds LH Jr: Tirofiban pro-
vides "platelet anaesthesia" during cardiopulmonary bypass
in baboons.  J Thorac Cardiovasc Surg 1997, 113:182-193.
13. Koster A, Kukucka M, Bach F, Meyer O, Fischer T, Mertzlufft F,
Loebe M, Hetzer R, Kuppe H: Anticoagulation during cardiopul-
monary bypass in patients with heparin-induced thrombocyto-
penia type II and renal impairment using heparin and the
platelet glycoprotein IIb/IIIa antagonist tirofiban.  Anesthesiol-
ogy 2001, 94:245-251.
14. Straub A, Azevedo R, Beierlein W, Wendel HP, Dietz K, Ziemer G:
Tirofiban (Aggrastat®) protects platelets and decrease plate-
let-granulocyte binding in an extracorporeal circulation model.
J Thorac Cardiovasc Surg 2006, 54:162-167.
15. Hollenberg SM, Kavinsky CJ, Parrillo JE: Cardiogenic shock.  Ann
Intern Med 1999, 131:47-59.
16. Venkataraman R, Kellum JA: Defining acute renal failure: the
RIFLE criteria.  J Intensive Care Med 2007, 22:187-193.
17. Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I,
Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van
Straaten H, Ronco C, Kellum JA: Continuous renal replacement
therapy: a worldwide practice survey. The beginning and end-
ing supportive therapy for the kidney (B.E.S.T. kidney)
investigators.  Intensive Care Med 2007, 33:1563-1570.
18. Greinacher A, Kiefel V, Klüter H, Kroll H, Pötzsch B, Riess H: Rec-
ommendations on platelet transfusion by the Joint Working
Party of the German Society of Transfusion Medicine (DGTI),
Thrombosis and Haemostasis Research (GTH), and Haemo-
tology and Oncology (DGHO).  Dtsch Med Wochenschr 2006,
131:2675-2679.
19. Mielke CH, Kaneshiro MM, Maher IA: The standardised normal
Ivy Bleeding Time and its prolongation by aspirin.  Blood 1969,
34:204-215.
20. Michelson AD: Flow cytometry: a clinical test of platelet
function.  Blood 1996, 87:4925-4936.
21. Shattil SJ, Hoxie JA, Cunningham M, Brass L: Changes in the
platelet membrane glycoprotein IIb-IIIa complex during plate-
let activation.  J Biol Chem 1985, 260:11107-11114.
22. Elstad MR, La Pine TR, Cowley FS, McEver RP, McIntyre TM, Pres-
cott SM, Zimmerman GA: P-selectin regulates platelet-activat-
ing factor synthesis and phagocytosis by monocytes.  J
Immunol 1995, 155:2109-2122.
23. Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Mor-
rissey JH, Prescott SM, Zimmerman GA: Activated platelets sig-
nal chemokine synthesis by human monocytes.  J Clin Invest
1996, 97:1525-1534.
24. Neumann FJ, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schömig
A: Effect of glycoprotein IIb/IIIa receptor blockade on platelet-
leukocyte interaction and surface expression of the leukocyte
integrin MAC-1 in acute myocardial infarction.  J Am Coll
Cardiol 1999, 34:1420-1426.
25. da Costa Martins P, Berk N van den, Ulfman LH, Koenderman L,
Hordijk PL, Zwaginga JJ: Platelet-monocyte complexes support
monocyte adhesion to endothelium by enhancing secondary
tethering and cluster formation.  Arterioscler Thromb Vasc Biol
2004, 24:193-199.
26. Morabito S, Guzzo I, Solazzo A, Muzi L, Luciani R, Pierucci A: Con-
tinuous renal replacement therapies: anticoagulation in the
critically ill at high risk of bleeding.  J Nephrol 2003,
16:566-571.
27. Koster A, Chew D, Merkle F, Gruendel M, Jurmann M, Kuppe H,
Oertel R: Extracorporeal elimination of large concentrations of
tirofiban by zero-balanced ultrafilration during cardiopulmo-
nary bypass: an in vitro investigation.  Anesth Analg 2004,
99:989-992.
28. Steinhubl SR, Tallex JD, Braden GA, Tcheng JE, Casterella PJ,
Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo
R, Sane DC, Saucedo JF, Jia GJ, Lincoff M, Theroux P, Holmes DR,
Teirstein PS, Kereiakes DJ: Point-of-care measured platelet
inhibition correlates with a reduced risk of an adverse cardiac
event after percutaneous coronary intervention. Results of the
GOLD (AU-Assessing Ultegra) multicenter study.  Circulation
2001, 103:2572-2578.Page 9 of 9
(page number not for citation purposes)
